Upcoming Ex-Dividend Dates for Kenvue, Winmark, and Rush Enterprises
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Source: NASDAQ.COM
Upcoming Ex-Dividend Dates: Kenvue Inc (KVUE), Winmark Corp (WINA), and Rush Enterprises Inc. (RUSHA) will trade ex-dividend on 11/12/25, with respective dividends of $0.2075, $0.96, and $0.19 scheduled for payment on 11/26/25, 12/1/25, and 12/12/25.
Expected Stock Price Adjustments: Following the ex-dividend date, KVUE shares are expected to open 1.23% lower, WINA by 0.23%, and RUSHA by 0.39%, based on their recent stock prices.
Dividend Aristocrats Contender: Winmark Corp is noted as a future contender for the "Dividend Aristocrats" index, having over 15 years of dividend increases, while Kenvue and Rush Enterprises have varying historical dividend yields.
Current Stock Performance: As of Monday trading, Kenvue Inc shares are up 2.5%, Winmark Corp shares are up 0.7%, and Rush Enterprises Inc. shares are up 3.3%.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy KVUE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on KVUE
Wall Street analysts forecast KVUE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KVUE is 18.86 USD with a low forecast of 17.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
1 Buy
7 Hold
0 Sell
Hold
Current: 17.200
Low
17.00
Averages
18.86
High
23.00
Current: 17.200
Low
17.00
Averages
18.86
High
23.00
About KVUE
Kenvue Inc. is a consumer health company. The Company’s differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, BAND-AID, Aveeno, Zyrtec, and Nicorette. It operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include pain care; cough, cold, and allergy; digestive health; smoking cessation; eye care; and other products. Self Care segments include brands such as Tylenol, Motrin, Nicorette, Benadryl, Zyrtec, Zarbee’s, ORSLTM, Rhinocort, and Calpol. The Skin Health and Beauty segment is focused on face and body care, as well as hair, sun, and other products. The Essential Health segment includes oral care, baby care, women’s health, wound care, and other products. Its portfolio includes Self Care, Skin Health and Beauty, and Essential Health products which connect with consumers across North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Kimberly-Clark and Kenvue Merger Approved by Shareholders
- Merger Approval: The merger between Kimberly-Clark (KMB) and Kenvue (KVUE) received overwhelming shareholder approval, with the transaction expected to close in the second half of 2026, marking a strategic consolidation of two major players in consumer health and personal care.
- Transaction Valuation: The cash-and-stock deal is valued at approximately $48.7 billion, with Kenvue shareholders set to receive $3.50 in cash plus 0.14625 shares of Kimberly-Clark per Kenvue share, ensuring shareholder interests are protected.
- Market Leadership: Post-merger, Kimberly-Clark shareholders will own about 54% of the combined entity, while Kenvue shareholders will hold approximately 46%, positioning the new company as a projected $32 billion leader in health and wellness, serving nearly half of the global population.
- Brand Integration Strategy: The merger combines Kimberly-Clark's tissue, baby, and personal care products with Kenvue's over-the-counter and consumer health brands, enhancing competitive strength in health, hygiene, and skincare markets.
Continue Reading
Kimberly-Clark's Acquisition of Kenvue Receives Shareholder Approval
- Shareholder Voting Results: Approximately 96% of Kimberly-Clark shareholders voted in favor of the acquisition of Kenvue at the Special Meeting, reflecting strong confidence in the merger and expected to enhance the company's leadership in global health and wellness.
- Transaction Timeline: The deal is anticipated to close in the second half of 2026, pending regulatory approvals and other customary conditions, with successful integration projected to create significant shareholder value and enhance market competitiveness.
- Integration Planning Progress: Kimberly-Clark and Kenvue leadership teams are actively collaborating on integration planning, aiming to accelerate innovation and expand brand influence, thereby enhancing customer satisfaction and loyalty.
- Optimistic Market Outlook: Kenvue's CEO stated that the merger will accelerate innovation and expand market reach, expected to provide more trusted brands to global consumers, further solidifying both companies' positions in the health and wellness sector.
Continue Reading